Addiction / 27.11.2025

[caption id="attachment_71578" align="aligncenter" width="500"]recovery-methadone-addiction Freepx Image[/caption]

Understanding Methadone and Its Role in Recovery

Methadone is one of the most widely used and well-researched medications for treating opioid use disorder (OUD). It helps reduce cravings, prevent withdrawal, and stabilize the brain so individuals can rebuild their lives with more clarity and control. But many people wonder whether they must complete a residential rehab program before they can begin methadone treatment. According to the National Institute on Drug Abuse (NIDA), methadone is a highly effective form of Medication-Assisted Treatment (MAT) and can be started as soon as a certified provider determines it is clinically appropriate: https://nida.nih.gov/  This means that you do not need to attend rehab before beginning methadone, though for some individuals, rehab may still be part of a comprehensive treatment plan.

Do You Need Rehab First?

The Short Answer: No

Methadone does not require a prior stay in inpatient rehab. Many people begin methadone as their first step in recovery, especially if they are experiencing withdrawal, unstable opioid use, or difficulty stopping on their own. A certified opioid treatment program (OTP) can evaluate your needs and start treatment without requiring residential care.

When Rehab May Be Recommended

Although it isn’t required, some individuals benefit from attending rehab before or alongside methadone. Rehab may be suggested if someone:
  • Has severe opioid use disorder
  • Is using multiple substances (polysubstance use)
  • Lacks stable housing
  • Is experiencing severe mental health symptoms
  • Needs a safe, structured environment to stabilize In these cases, combining residential treatment with methadone can provide comprehensive support.
Addiction, Author Interviews, COVID -19 Coronavirus, Opiods / 07.02.2023

MedicalResearch.com Interview with: [caption id="attachment_56276" align="alignleft" width="200"]Dr-Brian-Piper Dr. Piper[/caption] Brian Piper, PhD MS Assistant Professor of Neuroscience Center for Pharmacy Innovation & Outcomes Geisinger School of Graduate Education MedicalResearch.com: What is the background for this study? Response: Methadone is an evidence-based treatment of opioid use disorder (OUD) and pain. However, this Schedule II opioid can also cause respiratory depression, which can result in lethality. The need for supervised administration is a long-standing source of frustration in the U.S. for many opioid use disorder (OUD) methadone patients. However, there was an accommodation in early 2020 thanks to the COVID-19 pandemic. This involved extending the take-home supply to up to 28-days for stable patients and 14 days for less stable patients. Prior research found that the implementation of supervised administration in England greatly reduced methadone overdoses [1]. The primary objective of this study [2] from Geisinger Commonwealth School of Medicine was to determine if the relaxation of the take-home rules resulted in more methadone overdoses.
Addiction, Author Interviews, Opiods, Race/Ethnic Diversity / 10.09.2021

John A. Furst BS Geisinger Commonwealth School of Medicine MedicalResearch.com: What is the background for this study? Response: Methadone is an evidence-based pharmacotherapy for opioid detoxification, maintenance therapy, and pain management. However, accessibility of this treatment remains variable across much of the country. Methadone for the treatment of opioid use disorder (OUD) is exclusively provided by federally regulated opioid treatment programs (OTPs) and has provoked significant community-based and legal controversy regarding its role in the management of this condition. This has created disparities related to the distribution and access of methadone throughout the United States (U.S.). The goal of this study1 was to highlight the most recent pharmacoepidemiologic trends associated with methadone in the face of unique restrictions at the local, state, and federal levels.
Addiction, Author Interviews, HIV, Lancet / 10.08.2015

MedicalResearch.com Interview with: Dr. Keith Ahamad, a clinician scientist at the BC Centre for Excellence in HIV/AIDS and a Family Doctor trained and certified in Addiction Medicine. He is Division Lead for Addiction Medicine in the department of Family and Community Medicine at Providence Health Care, and is also an addiction physician at the St. Paul’s Addiction Medicine Consult Service, the Immunodeficiency Clinic and Vancouver Detox. He is also Lead Study Clinician for CHOICES, a US National Institutes of Drug Abuse (NIDA) funded clinical trial looking at an opioid receptor blocker (Vivitrol) to treat opioid or alcohol addiction in HIV positive patients.Dr. Keith Ahamad, a clinician scientist at the BC Centre for Excellence in HIV/AIDS and a Family Doctor trained and certified in Addiction Medicine. He is Division Lead for Addiction Medicine in the department of Family and Community Medicine at Providence Health Care, and is also an addiction physician at the St. Paul’s Addiction Medicine Consult Service, the Immunodeficiency Clinic and Vancouver Detox. He is also Lead Study Clinician for CHOICES, a US National Institutes of Drug Abuse (NIDA) funded clinical trial looking at an opioid receptor blocker (Vivitrol) to treat opioid or alcohol addiction in HIV positive patients. MedicalResearch: What is the background for this study? Dr. Ahamad: Previous methadone research has mostly been done in restrictive settings, such as the USA, where methadone can only be dispensed through restrictive methadone programs and cannot be prescribed through primary care physician’s offices. Since a systematic review in 2012, randomised controlled trials have compared methadone treatment provided at restrictive specialty clinics with primary care clinics, which have shown the benefits of primary care models of methadone delivery on heroin treatment outcomes, but not on HIV incidence. MedicalResearch: What are the main findings? Dr. Ahamad: After adjusting for factors commonly associated with HIV, methadone remained independently associated in protecting against HIV in this group of injection drug users. Those study participants who were not prescribed methadone at baseline were almost four times more likely to contract HIV during study follow up. MedicalResearch: What should clinicians and patients take away from your report? Dr. Ahamad: Methadone is an effective medication in treating opioid addiction. Through international randomized control trials, we already know that when prescribed though primary care offices, access to this life-saving medication is increased, effective, and increases patient satisfaction. Now, through our study, we have evidence that when delivered in this manner, it also decreases the spread of HIV.